Effect of Kalonji in Polycystic Ovary

Efficacy of Kalonji (Nigella sativa Linn. seeds) in Polycystic Ovarian Syndrome: A Randomized Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071331

Enrollment

Registered

2024-07-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Powdered Kalonji (Nigella sativa Linn. Seeds) : Kalonji powder filled in capsules (each weighing 500mg) and one capsule thrice in a day will be given orally with water for 90 days Contr

Eligibility

Inclusion criteria

Inclusion criteria: Married & Unmarried females 18 years and above Rotterdam criteria (any two out of three) Clinical or biochemical hyperandrogenism Evidence of oligo-anovulation Polycystic appearing-ovarian morphology on Ultrasound BMI above 25kg per meter square

Exclusion criteria

Exclusion criteria: Pregnant lactating and menopausal women Patients with systemic and other endocrinal illness History of malignancy Patients with other pelvic pathology Patients on oral contraceptive pills and IUCDs

Design outcomes

Primary

Measure	Time frame
Regulation of menstrual cycle Change in polycystic ovarian morphology in USGTimepoint: 90 days	—

Secondary

Measure	Time frame
Weight reduction Reduction in BMI Decreased Waist to Hip Ratio Lipid profile Decreases clinical sign of androgen excess Ferriman Gallwey score Decrease in Acanthosis nigricans score Conception rate in married femalesTimepoint: 90 days	—

Countries

India

Contacts

Public ContactSUMBUL ALAM

State Takmeel-ut-Tib College and Hospital

dr.mroqaiya@gmail.com919632560839

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026